Abstract
Background: High-dose chemotherapy followed by autologous stem cell transplantation (ASCT) is the standard of care for patients with relapsed Hodgkin's lymphoma (HL). However, there is currently little information on the predictors of outcome for patients whose disease recurs after ASCT. Methods: Five hundred and eleven adult patients with relapsed HL after ASCT from EBMT-GITMO databases were reviewed. Results: Treatments administered following ASCT failure included conventional chemotherapy and/or radiotherapy in 294 (64%) patients, second ASCT in 35 (8%), and alloSCT in 133 (29%). After a median follow-up of 49 months, overall survival (OS) was 32% at 5 years. Independent risk factors for OS were early relapse (
Original language | English |
---|---|
Article number | mdt206 |
Pages (from-to) | 2430-2434 |
Number of pages | 5 |
Journal | Annals of Oncology |
Volume | 24 |
Issue number | 9 |
DOIs | |
Publication status | Published - Sep 2013 |
Keywords
- Autologous stem cell transplantation
- Hodgkin's lymphoma
- Relapse
ASJC Scopus subject areas
- Oncology
- Hematology